Chronic painful HIV-associated neuropathy
Conditions
Interventions
Product Name: Cannabidivarin (CBDV)
Product Code: GWP42006
Pharmaceutical Form: Oral solution
INN or Proposed INN: cannabidivarin
Current Sponsor code: GWP42006
Other descriptive name: CANNABIDIVARIN
Sponsors
Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Male and female patients with chronic, painful HIV-associated neuropathy (NRS-score =4); women who are post-menopausal for more than one year can participate in this study; female patients of child-bearing potential are allowed to participate in this study only if they are permanently sterilised (e.g. tubal occlusion, hysterectomy) or if they provide a negative pregnancy test and are willing to use a highly effective method of contraception (e.g. hormonal contraceptives) during the course of the study and for three months thereafter •Age: 18-65 years •Body mass index (BMI): 18-30 kg/m2 •Sufficient knowledge of the German language •Signed written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 45 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5
Exclusion criteria
Exclusion criteria: •Individuals dependent on the sponsor, the trial site or the investigator •Individuals housed in institutions due to official or judicial orders •Co-incident severe diseases of the central nervous system (e.g. dementia) •Co-incident major psychiatric conditions •Acute disorders with functional limitations and/or limitations of neurological assessment •Limited mental capacity or knowledge of the German language •Chronic or previous abuse of recreational drugs, drugs and/or alcohol •Pregnancy and lactation as well as planning pregnancy during the course of the study and for three months thereafter •Men and women of childbearing potential not using adequate contraception during the clinical trial and three months thereafter •Intolerance to the study medication or to one of the components of the study medication •Hepatic diseases where: - the level of ALT exceeds three times the upper limit of normal or the level of AST exceeds three times the upper limit of normal and the bilirubin exceeds two times the upper limit of normal or the INR exceeds 1,5 times the upper limit of normal - the levels of ALT or AST exceeds three times the upper limit of normal in combination with symptoms (fatigue, nausea, vomiting, pain or tenderness in the right upper quadrant of the abdomen, fever, rash, and/or eosinophilia) - the levels of ALT or AST alone exceed eight times the upper limit of normal - the levels of ALT or AST alone exceed five times the upper limit of normal longer than two weeks •Chronic renal insufficiency (with significant deviating levels of normal) •EKG-Parameters outside following reference ranges: PR-interval: 120 ms (lower limit), 220 ms (upper limit); QRS-duration: 0 ms (lower limit), 120 ms (upper limit); QT-interval: 0 ms (lower limit), 500 ms (upper limit); QTcF-Interval (males): 0 ms (lower limit), 430 ms (upper limit), QTcF (females): 0 ms (lower limit), 450 ms (upper limit) •Clinical significant cardiovascular or metabolic diseases: uncontrollable hypertension (lower limit: 90/40 mmHg, upper limit: 140/90 mmHg (18-45 years), 160/90 mmHg (>45 years)); severe heart insufficiency (NYHA = III); abnormal heart rate (lower limit: 40 min-1 (18-45 years), 50 min-1 (>45 years), upper limit: 90 min-1); heart attack within the past 12 months •Active participation in other clinical trials three months before or within this clinical study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Pain reduction when using cannabidivarin (CBDV) as compared to placebo;Secondary Objective: •Does CBDV have any effects on special pain characteristics? •Is rescue medication needed? •Is CBDV sufficiently safe? •Does CBDV have an effect on physical and mental functions? •Does patients' expectation have any influence on the effect of CBDV and placebo? •Does CBDV have any influence on patients' acute subjective response? •Does CBDV have an impact on the quality of life and sleep? •Is a response to the therapy with CBDV associated with the genotype of the patient? ;Primary end point(s): Amelioration of pain intensity („baseline“) by 20%, measured based on the reduction of the total score on a 11-point numeric rating scale (NRS) after CBDV application as compared to placebo.;Timepoint(s) of evaluation of this end point: At the end of the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): •Analysis of specific pain parameters •Analysis of rescue medication •Analysis of side effects •Analysis of parameters of physical and mental functions •Analysis of patients’ expectation on the clinical effect •Analysis of patients' acute subjective response •Analysis of quality of life and sleep •Genotyping;Timepoint(s) of evaluation of this end point: •Specific pain characters: at the beginning of the first, at the end of the second baseline and at the end of both treatment phases •Rescue medication: daily, throughout the whole clinical trial, during the follow-up period •Side effects: daily evaluation throughout both treatment phases, wash-out phase, the second baseline and the follow-up period •Physical and mental functions: at the beginning of the first baseline, at the end of the second baseline and at the end of both treatment phases •Patients' expectation: at the end of both treatment phases •Patients' acute subjective response: daily evaluation, within the first week of both treatment phases •Analysis of quality of life and sleep: at the end of first and second baseline, at the end of both treatment phases | — |
Countries
Germany
Contacts
Public ContactClinical trial information
Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF)
Outcome results
None listed